Emory Alzheimer's Disease Research Center

总结/摘要：临床核心 临床核心的主要目标是支持和加强戈伊苏埃塔阿尔茨海默氏症的研究工作 疾病研究中心（ADRC）在埃默里推进尖端研究，以确定新的生物标志物， 治疗目标，同时减少AD研究中的种族差异。临床核心在 Goizueta ADRC通过吸引不同的研究参与者和驾驶活动，反映了该中心的整体 主题.为了实现这些目标，临床核心有完善的流程来招募，跟踪， 描述并保留一组纵向研究参与者，并有效协调活动 并与ADRC的其他部门和外部合作伙伴共享数据。在本资助期内， 临床核心建立了纵向生物标志物收集，以支持高优先级的多中心研究 项目，包括加速AD医学合作伙伴关系（AMP-AD）和分子机制， AD的血管病因（M2 OVE-AD）。LBC的成功开发导致了一个有竞争力的补充， 建立生物标志物核心，该核心将继续作为ADRC更新的核心组成部分。此外，在 在本周期，我们成功地在我们的雄心勃勃的目标，增加我们的UDS队列的多样性，通过招收一个 同等数量的新的非洲裔美国人和白人参与者。这一成功支持了建立 少数民族参与核心（MEC）。本次更新的具体目标是：1）建立和维持一个 多样化的研究参与者队列，以支持当前ADRD研究的优先事项; 2） 通过协调样本采集和临床表型分析程序推进生物标志物发现工作 在多个相关项目和群组之间进行;以及3）扩大和整合ADRD的活动，包括 血管性认知障碍和路易体病。实现这些具体目标将推动 国家阿尔茨海默病项目法案（NAPA）中确定的优先事项和NIH ADRD的建议 研究峰会，并将最终导致有效的诊断工具和治疗个人的痛苦 AD及相关疾病的症状

SUMMARY/ABSTRACT: CLINICAL CORE The primary goals of the Clinical Core are to support and enhance research efforts of the Goizueta Alzheimer’s Disease Research Center (ADRC) at Emory to advance cutting-edge research to identify novel biomarkers and therapeutic targets while reducing racial disparities in AD research. The Clinical Core plays a central role in the Goizueta ADRC by engaging diverse research participants and driving activities that reflect the Center’s overall themes. To accomplish these goals, the Clinical Core has well-established processes to recruit, track, characterize, and retain a cohort of longitudinal research participants and to effectively coordinate activities and share data with other components of the ADRC and external partners. In the current funding period, the Clinical Core established a Longitudinal Biomarker Collection to support high-priority multicenter research projects, including the Accelerating Medicine Partnership for AD (AMP-AD) and Molecular Mechanisms of the Vascular Etiology of AD (M2OVE-AD). Successful development of the LBC led to a competitive supplement to establish a Biomarker Core which will continue as a Core component in the ADRC renewal. Also, during the current cycle, we succeeded in our ambitious goal for increasing the diversity of our UDS cohort by enrolling an equal number of new African-American and Caucasian participants. This success supported the establishment of a Minority Engagement Core (MEC). Specific Aims for this renewal are to 1) Establish and maintain a diverse cohort of well-characterized research participants to support priorities in current ADRD research; 2) Advance biomarker discovery efforts by harmonizing procedures for sample collection and clinical phenotyping across multiple related projects and cohorts; and 3) Expand and integrate activities in ADRD, including vascular cognitive impairment and Lewy body diseases. Achieving these Specific Aims will advance the priorities identified in the National Alzheimer’s Project Act (NAPA) and recommendations from the NIH ADRD Research Summits, and will ultimately lead to effective diagnostic tools and treatments for individuals suffering from AD and related disorders.